Delana Patrics Fontenot, | |
2438 Jake Dr Apt 4b, Opelousas, LA 70570-7719 | |
(337) 278-6554 | |
Not Available |
Full Name | Delana Patrics Fontenot |
---|---|
Gender | Female |
Speciality | Case Manager/care Coordinator |
Location | 2438 Jake Dr Apt 4b, Opelousas, Louisiana |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1982228284 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
164W00000X | Licensed Practical Nurse | 270083 (Louisiana) | Secondary |
171M00000X | Case Manager/care Coordinator | (* (Not Available)) | Primary |
Mailing Address | Practice Location Address |
---|---|
Delana Patrics Fontenot, 2438 Jake Dr Apt 4b, Opelousas, LA 70570-7719 Ph: (337) 278-6554 | Delana Patrics Fontenot, 2438 Jake Dr Apt 4b, Opelousas, LA 70570-7719 Ph: (337) 278-6554 |
News Archive
Many patients previously diagnosed with a penicillin allergy can have their allergy label removed after testing and safely undergo treatment with penicillin medications, according to a study published in American Journal of Respiratory and Critical Care Medicine.
VIA Pharmaceuticals, Inc., a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic diseases, today announced that Dr. Rebecca Taub, Senior Vice President Research & Development will present "Liver Directed Beta Agonist for Targeting Cardiometabolic Disease", and will discuss the Company's cardio-metabolic product portfolio, including VIA's inhibitor of 5 Lipoxygenase, its THR Beta Agonist, and its DGAT1 development programs, at the Cambridge Healthtech Institute Seventh International Discovery on Target 2009 program, on November 3, 2009 in Boston, MA.
Optogenetics is a new field of research that introduces light-sensitive proteins into cells in a genetically targeted manner, for example, to obtain information on signalling pathways and the function of neurons in a living organism.
Uroplasty, Inc., announced today that the United Kingdom's National Institute for Health and Clinical Excellence issued guidance on percutaneous tibial nerve stimulation for the treatment of faecal incontinence.
› Verified 7 days ago